Jan 10, 2022 / 02:45PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this morning with Joaquin Duato, who's assuming the CEO role at J&J earlier this year. So Joaquin, Happy New Year, and great to be speaking with you today.
Maybe just to kick off the conversation, and I know this is your first presentation to The Street as CEO, would love to hear about your top priorities as you move into the role.
Joaquin Duato - Johnson & Johnson - CEO & Director
Thank you, Chris, and thank you, everybody, for joining. As you can imagine, I am deeply honored to be the eighth CEO of this remarkable company, Johnson & Johnson. And I am very excited about taking the role now in what I think is a moment of opportunity for health care in which Johnson & Johnson, it's in a very good position to continue to create value and accelerate growth by focusing mainly on what has made us great, differentiation based on science and technology.
Johnson & Johnson at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot